Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes extensive molecular simulations of the target protein alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that considers conformational mobility in both free and complex states. Potential binding pockets are examined on the protein-protein interaction interface and in distant allosteric sites to cover all possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P15391

UPID:
CD19_HUMAN

ALTERNATIVE NAMES:
B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12

ALTERNATIVE UPACC:
P15391; A0N0P9; F5H635; Q96S68; Q9BRD6

BACKGROUND:
The B-lymphocyte antigen CD19 is a key player in the immune response, acting as a coreceptor that lowers the activation threshold for B-cells. Its involvement is crucial for normal B-cell differentiation, proliferation, and the production of immunoglobulins in response to antigens. CD19's role is underscored by its necessity for the generation of high-affinity antibodies, highlighting its importance in the adaptive immune system.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of B-lymphocyte antigen CD19 could open doors to potential therapeutic strategies, especially in the context of Immunodeficiency, common variable, 3. This condition, marked by a failure in B-cell differentiation and impaired immunoglobulin secretion, could benefit from targeted interventions aimed at modulating CD19 activity to restore immune function.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.